Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Introduction: Immune checkpoint inhibitors combined with platinum-based chemotherapy have become the standard first-line treatment for HER2-negative unresectable advanced or recurrent gastric and gastroesophageal junction (GEJ) cancers. However, many...
Introduction: Despite curative surgery for stage I–III colorectal cancer (CRC), 10–30% of patients develop recurrence, most commonly within the first two years. Conventional postoperative surveillance using CT scans...
Introduction: Acute kidney injury (AKI) is a frequent and serious complication following cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), particularly with cisplatin-based regimens. This study evaluated whether...
Introduction: Claudin 18.2 (CLDN18.2) has emerged as a key therapeutic target in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The Phase III CLARITY-Gastric01 trial evaluated sonesitatug vedotin, an anti-CLDN18.2...
Introduction: Individuals with Lynch syndrome (LS) require lifelong surveillance for colorectal and upper gastrointestinal cancers, yet adherence to screening recommendations remains suboptimal. This study evaluated whether a dedicated...
Introduction: Cancer-related symptoms often persist despite guideline-based pharmacologic treatment, affecting quality of life throughout the cancer journey. This review summarizes the current evidence, safety considerations, and practical implementation...
Introduction: Local ablative therapy plays an important role in managing oligometastatic liver disease when surgical resection is not feasible. This review compares stereotactic body radiotherapy (SBRT) and percutaneous...
Introduction: Borderline resectable cholangiocarcinoma (CCA) carries a poor prognosis because many patients cannot undergo curative surgery. Following the approval of gemcitabine–cisplatin–durvalumab (GCD) in advanced biliary tract cancer, this...
Introduction: Immune checkpoint inhibitors have revolutionized the treatment of dMMR/MSI-H rectal cancer, but most patients worldwide continue to receive total neoadjuvant therapy (TNT) as standard care. This international...
Introduction: Immune checkpoint inhibitors (ICIs) are the standard first-line treatment for MSI-H/dMMR metastatic colorectal cancer (mCRC). In the absence of direct head-to-head trials, this reconstructed individual patient data...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.